Key Quantitative Figures

The proposed preferential issue is for 2,00,00,000 (Two Crore) convertible warrants, each convertible into one equity share.

  • Total Issue Size: ₹47,00,00,000 (Rupees Forty-Seven Crores Only)
  • Issue Price per Warrant: ₹23.50 (Rupees Twenty-Three and Fifty Paise Only)
  • Breakdown of Proceeds Utilization:
  • Working Capital Requirements: ₹35,00,00,000
  • Capital Expenditure & Business Growth: ₹5,00,00,000
  • General Corporate Purposes: ₹7,00,00,000
  • Floor Price Calculation (as per SEBI ICDR Reg. 164(1)):
  • 90-day VWAP (NSE): ₹23.18 per share
  • 10-day VWAP (NSE): ₹22.16 per share
  • Final Floor Price: ₹23.18 per share (the higher of the two)
  • Registered Valuer's Fair Value: ₹18.14 per share (as per revised report dated July 03, 2026)

Dates of Action

  • Original Postal Ballot Notice dispatch date: June 12, 2026
  • NSE observation dates: June 17, 2026 and June 29, 2026
  • BSE observation date: June 29, 2026
  • Corrigendum issuance date: July 06, 2026
  • Last date for remote e-voting: July 12, 2026 (5:00 PM IST)
  • Warrant conversion period: Within 18 (Eighteen) months from the date of allotment

Parties Involved

  • Stock Exchanges: National Stock Exchange of India Limited (NSE), BSE Limited (BSE)
  • Registered Valuer: Ms. Kavita Joshi, Chartered Accountant (Membership No. 190551) and Registered Valuer (IBBI Registration No. IBBI/RV/06/2025/15868)
  • Practicing Company Secretary: Mr. Rajkumar Chandulal Gupta of Rajkumar Gupta & Co. (Membership No. 11272; Certificate of Practice No. 18582)
  • Company Secretary & Compliance Officer: Mehaboobsab Mahmadgous Chalyal (Membership No.: A67502)

Purpose/Rationale

The proceeds from the preferential issue are intended for:

1. Working Capital Requirements: To meet ongoing operational needs.

2. Capital Expenditure & Business Growth: For capacity augmentation, modernization of facilities, strengthening supply chain and distribution infrastructure, product diversification, market expansion, technology and process improvements, and strategic investments.

3. General Corporate Purposes: Including business exigencies, administrative expenses, strategic initiatives, technology upgrades, and regulatory expenses.

The Board of Directors retains flexibility to reallocate the proceeds among these objects by ±10% of the allocated amount for each object, as permitted by NSE and BSE circulars dated December 13, 2022.

Financial & Operational Impact

The entire issue proceeds of ₹47 crore are proposed to be utilized. The utilization is planned to occur in phases based on the receipt of funds from the allotment and subsequent conversion of warrants. The tentative timelines for utilization are:

  • Working Capital: As estimated by management (no specific timeline provided)
  • Capex & Growth: 12 months from receipt of funds
  • General Corporate Purposes: 18 months from receipt of funds

Pending utilization, unutilized proceeds may be temporarily invested as per applicable law.

Capital Structure Impact

The issue involves the potential creation and conversion of 2,00,00,000 warrants, which would result in the issuance of an equivalent number of equity shares upon full conversion, leading to dilution of existing shareholding. The disclosure confirms the issue does not exceed 5% of the post-issue fully diluted share capital and will not result in any change in control or management.

Additional Disclosures & Undertakings

  • The company undertakes to re-compute the price of the warrants or the number of shares to be allotted if required under Regulation 166 of SEBI ICDR Regulations.
  • If any additional amount from such re-computation is not paid by the warrant holder, the warrants and resultant shares will remain locked-in until payment is made.
  • The Equity Shares have been listed for over 90 days, making Regulation 164(3) of SEBI ICDR Regulations on price re-computation inapplicable.
  • The revised valuation report (July 03, 2026) and a revised compliance certificate from the Company Secretary (July 03, 2026) are available on the company's website and for electronic inspection by members until July 12, 2026.

Shareholder Voting Instructions

Members who cast their e-votes prior to receiving this corrigendum and wish to modify their vote based on this new information can do so by sending an email to the scrutinizer at cs@cnassociates.in with a copy to helpdesk.evoting@cdslindia.com on or before 5:00 PM IST on July 12, 2026.

The Corrigendum and all associated documents are available on the company's website (https://mukkaproteins.com/corporate-announcements/) and the websites of the stock exchanges (NSE: www.nseindia.com, BSE: www.bseindia.com).